# Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors

> **NCT02900157** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 42 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** MEDI9090
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT02900157
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-09
- **Primary completion:** 2020-01-23
- **Final completion:** 2020-01-23
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02900157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02900157, "Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02900157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*